Updated:
Abdullatif Jamjoom & Bros
Mahmoud Yousuf Jamjoom chairs a Jeddah family office founded in 1945, built on pharmaceuticals, distribution, and real estate.
Abdullatif Jamjoom & Bros
Founded in 1945, Abdullatif Jamjoom & Bros operates as the single-family office for the Jamjoom family, whose wealth originated in pharmaceuticals and diversified trading. The office coordinates a web of operating subsidiaries — Jamjoom Pharma, Jamjoom Motors, and Jamjoom Medical among them — that function as exclusive regional distributors and licensees for multinational brands. The family’s publicly listed pharmaceutical arm, Jamjoom Pharmaceuticals Factory Company (4015.SE), formalized a portion of that legacy, with Mahmoud Yousuf Jamjoom as Chairman. The portfolio spans healthcare services, mobility, real estate, and industrial sectors. Jamjoom Pharma holds licensing and manufacturing agreements for ophthalmic products with Japan’s Santen Pharmaceutical and Brazil’s Aché Laboratórios Farmacêuticos. Jamjoom Motors operates as the exclusive dealer for Peugeot (Stellantis) in Saudi Arabia’s Western Region and an exclusive distributor for Chinese automaker Dongfeng passenger vehicles since 2022. Jamjoom Medical distributes Johnson & Johnson Vision Care, Bausch + Lomb, Medtronic, and Alcon products. The real estate book includes mixed-use properties in Jeddah and Riyadh, such as the Jamjoom Commercial Center and the Riyadh North Gate Project. The office is anchored in Jeddah with an additional operational presence in Riyadh. The Jamjoom Foundation for Charitable Works sits alongside the commercial activities. Tarek Hosni runs the listed pharmaceutical entity as CEO. The family’s engagement with the Jeddah Chamber of Commerce & Industry, where Mahmoud Yousuf Jamjoom serves on the board, reflects a long-standing local institutional network. The firm’s structure is unusual among Gulf family offices: rather than operating as a passive allocator, Abdullatif Jamjoom & Bros functions as an active holding company managing exclusive, long-duration distribution partnerships. This hybrid operator-investor model embeds the office directly in commercial territory that external fund managers cannot easily replicate.
General information
Firm type
Single Family Office
Year founded
1945
AUM
Undisclosed
Location
Region
Middle East
Country
Saudi Arabia
City
Jeddah
Corporate office
Jeddah, Saudi Arabia
Additional offices
Riyadh, Saudi Arabia
Principals
Mahmoud Yousuf Jamjoom
Chairman, Jamjoom Pharmaceuticals Factory Company
Mohammed Yousuf Jamjoom
Vice Chairman, Jamjoom Pharmaceuticals Factory Company
Ahmed Yousuf Jamjoom
Board Member, Jamjoom Pharmaceuticals Factory Company
Tarek Hosni
CEO, Jamjoom Pharmaceuticals Factory Company
Sector focus
Frequently asked questions
Who runs investment decisions at Abdullatif Jamjoom & Bros?
Direction sits with family principals Mahmoud Yousuf Jamjoom (Chairman), Mohammed Yousuf Jamjoom (Vice Chairman), and Ahmed Yousuf Jamjoom (Board Member) through their oversight of the listed entity Jamjoom Pharmaceuticals Factory Company and the broader group subsidiaries. The office does not disclose a dedicated CIO or investment committee structure externally.
How does the firm source its deals?
The firm sources through long-term operating partnerships and licensing agreements with multinational corporations. Subsidiaries like Jamjoom Motors and Jamjoom Medical function as exclusive regional partners for brands including Dongfeng, Peugeot, Johnson & Johnson Vision Care, and Medtronic — deal flow is generated by winning and maintaining these commercial rights rather than by participating in auction processes.
Is Abdullatif Jamjoom & Bros a passive investment office or an operating company?
It is a hybrid. The office functions as a holding company that actively operates distribution, manufacturing, and real estate businesses. This contrasts with family offices that principally allocate to external funds. The Jamjoom Pharma listing on the Saudi Exchange makes a portion of the group’s value visible to public markets.
Does Abdullatif Jamjoom & Bros invest in external funds or only direct deals?
The firm operates almost entirely through direct subsidiary investments, licensing agreements, and real estate holdings. There is no public evidence of a significant fund commitment program, which aligns with its operator-centric posture rather than an allocator model.
Where does the underlying wealth come from?
Wealth originated in pharmaceuticals, and the family expanded into diversified trading and distribution. The Jamjoom name is tied to one of Saudi Arabia’s oldest continuous pharmaceutical manufacturing and distribution businesses, now partially held via the listed company Jamjoom Pharmaceuticals Factory Company.
Does the family maintain philanthropic structures?
Yes. The Jamjoom Foundation for Charitable Works is a separate philanthropic vehicle that sits alongside the commercial operating entities. Its specific grant-making activities and endowment size are not publicly detailed.
What is the firm’s posture on co-investments alongside external partners?
The firm does not advertise co-investment programs with external GPs. Its disclosed relationships are business partnerships — exclusive distribution and licensing agreements — rather than pooled private equity co-investments.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: